Two million patients worldwide suffer from retinitis pigmentosa (RP), the most common form of Rod‑Cone Dystrophy (RCD), and there is still no treatment available for most patients.
Unlike traditional gene therapies intended for patients whose disease is caused by a specific genetic variant, gene-independent gene therapies are a new class of medicines which holds the potential to provide treatment regardless of the underlying genetic cause.
Status & Location
33
The PRODYGY study will recruit a total of 33 patients in the U.S. and will take place at:
UPMC Vision Institute
1622 Locust Street, Pittsburgh, PA 15213
Travel and accommodation will be arranged for study participants and their caregivers through Scout Clinical.
About the Study
PRODYGY is a clinical study evaluating the potential of an investigational drug called SPVN06 for the treatment of retinitis pigmentosa (RP).
Learn More